Literature DB >> 17284712

With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.

Rabiya S Tuma.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17284712     DOI: 10.1093/jnci/djk073

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

2.  Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).

Authors:  Fei Fei; Min Lim; Sabine Schmidhuber; Jürgen Moll; John Groffen; Nora Heisterkamp
Journal:  Mol Cancer       Date:  2012-06-21       Impact factor: 27.401

3.  Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

Authors:  Yun Dai; Shuang Chen; Charis A Venditti; Xin-Yan Pei; Tri K Nguyen; Paul Dent; Steven Grant
Journal:  Blood       Date:  2008-05-27       Impact factor: 22.113

4.  Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Authors:  N Widmer; L A Decosterd; S Leyvraz; M A Duchosal; A Rosselet; M Debiec-Rychter; C Csajka; J Biollaz; T Buclin
Journal:  Br J Cancer       Date:  2008-05-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.